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Abstract
Mendelian randomization is the use of genetic variants to assess the effect of interven-
ing on a risk factor using observational data. We consider the scenario in which there
is a pharmacomimetic (that is, treatment-mimicking) genetic variant that can be used
as a proxy for a particular pharmacological treatment that changes the level of the
risk factor. If the association of the pharmacomimetic genetic variant with the risk
factor is stronger in one subgroup of the population, then we may expect the effect
of the treatment to be stronger in that subgroup. We test for gene–gene interactions
in the associations of variants with a modifiable risk factor, where one genetic variant
is treated as pharmacomimetic and the other as an effect modifier, to find genetic
subgroups of the population with different predicted response to treatment. If indi-
vidual genetic variants that are strong effect modifiers cannot be found, moderating
variants can be combined using a random forest of interaction trees (RFIT) method
into a polygenic response score, analogous to a polygenic risk score for risk prediction.
We illustrate the application of the method to investigate effect heterogeneity in the
effect of statins on low-density lipoprotein cholesterol. [196 words]
Keywords: Mendelian randomization, effect heterogeneity, polygenic modelling, in-
strumental variable, causal inference.
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Introduction
Genetic variants can be treated as proxies for treatments to assess the effect of inter-
vening on a particular biological pathway using observational data [Thanassoulis and
O’Donnell, 2009; Plenge et al., 2013]. For example, 3-hydroxy-3-methylglutaryl–coenzyme
A reductase (HMGCR) inhibitors (known as statins) have been developed to reduce
levels of low-density lipoprotein (LDL) cholesterol. Variants in the HMGCR gene
region that predispose individuals to having higher or lower average levels of LDL-
cholesterol can be used to predict the effect of HMGCR inhibitors on disease outcomes
[Khera and Rader, 2009]. Associations between the HMGCR variants and coronary
artery disease risk suggest that statins should reduce coronary artery disease risk
[Ference et al., 2015], as has been observed in clinical trials [Cholesterol Treatment
Trialists’ Collaboration, 2005]. The approach of using genetic variants to make causal
inferences from observational data is known as Mendelian randomization [Davey Smith
and Ebrahim, 2003; Burgess and Thompson, 2015].
An extension of Mendelian randomization known as ‘factorial Mendelian random-
ization’ uses genetic variants in two gene regions to assess treatment interactions [Rees
et al., 2019]. For example, genetic variants in the HMGCR gene region, representing
proxies for statins, and genetic variants in the proprotein convertase subtilisin–kexin
type 9 (PCSK9 ) gene region, representing proxies for PCSK9 inhibitors, showed no
interaction in their associations with either LDL-cholesterol or coronary artery disease
[Ference et al., 2016]. This suggests statins should lower LDL-cholesterol when used
in conjunction with PCSK9 inhibitors, with no dilution in their effect. Alternatively,
we can consider the interaction between an HMGCR variant and a genetic variant in
a gene region that does not correspond to a pharmacological intervention, but instead
is viewed as a stratifying variable. In this case, a statistical interaction would be
interpreted as effect modification – the association of the HMGCR variant (and, by
inference, the effect of statins) differs for individuals in different genetic subgroups
defined by the stratifying variable [VanderWeele, 2015]. Effect modification has im-
plications for precision medicine, as individuals for whom statins are more effective
could be prescribed statins earlier in life. Henceforth, when considering gene–gene
interactions, we interpret variants in one gene region as proxies for the treatment
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(referred to as pharmacomimetic variants) and other variants as stratifying variables
(referred to as moderating variants).
Few interactions between genetic variants have been robustly demonstrated [Cordell,
2009]. There are several possible reasons for this: in particular, i) genetic variants
typically have small effects on phenotypes and interaction effects are generally smaller
in magnitude than main effects; and ii) hypothesis testing approaches must incorpo-
rate correction for multiple testing, which lowers power to detect a true interaction.
In the context of risk prediction, polygenic risk scores have been used successfully to
overcome the problems of small effects and multiple testing. By summing the contri-
butions of large numbers of variants across the whole genome into a single univariable
score, prediction is improved compared to approaches that take information on a small
number of variants [Dudbridge, 2013; Inouye et al., 2018]. This suggests the possibil-
ity of using a similar approach to construct genetic subgroups of the population which
differ in their predicted response to pharmacological treatment, even if no individual
variants can be found that have a strong gene–gene interaction.
In this paper, we introduce an agnostic approach to create a composite polygenic
response score that predicts treatment effect heterogeneity similarly to a polygenic risk
score for risk prediction. We first establish the feasibility and validity of our approach
through a simulation study. Next, as a proof-of-concept example, we demonstrate the
approach for the effect of statins on LDL-cholesterol. We first construct a pharma-
comimetic score for statins from genetic variants proximal to the HMGCR gene region
which have been shown to be associated with LDL-cholesterol [Ference et al., 2016].
We then perform a genome-wide search for moderating variants in the training subset
of the data, and combine these variants using the random forest of interaction trees
(RFIT) method [Su et al., 2018, 2009]. We proceed to verify in the validation subset
whether the predicted treatment effects for different genetic subgroups are more vari-
able than expected solely based on chance, and consider the impact of leaf node sizes
and interaction significance thresholds on the variability of estimates. We conclude
by discussing the applicability of this approach to wider practice in the emerging area
of precision medicine.





We consider a risk factor xi for individuals i = 1, . . . , N , a pharmacomimetic genetic
variant zi which can be considered as a proxy for a particular intervention on the
risk factor, J candidate moderating variants gij where j = 1, . . . , J , and K measured
covariates cik where k = 1, . . . , K. The pharmacomimetic genetic variant does not
have to be one single nucleotide polymorphism (SNP), but could instead be a weighted
score, representing the predicted values of the risk factor based on genetic variants in
the pharmacomimetic gene region. This would be a worthwhile strategy if there were
multiple variants independently associated with the risk factor in that gene region.
We consider the following linear regression model:
xi = β0j + β1jzi + β2jgij + β3jzigij +
K∑
k=1
βk+3,jcik + εi for i = 1, . . . , N (1)
The main parameter of interest is β3j, representing the interaction between the phar-
macomimetic genetic variant and the jth moderating variant. The marginal associa-
tion between the pharmacomimetic genetic variant and the risk factor is β1j + β3jgij.
If β3j = 0, then the association between the pharmacomimetic genetic variant and the
risk factor does not depend on the value of gij. Whereas if β3j 6= 0, then the associa-
tion between the pharmacomimetic genetic variant and the risk factor is stronger for
some values of gij.
Equation 1 could be fitted for each of the j = 1, . . . , J moderating variants sepa-
rately in a genome-wide search. If we find a genetic variant with statistically robust
evidence for an interaction, then we can use this variant to divide the population into
genetic groups which differ in their expected response to the treatment. For exam-
ple, if the marginal association between the pharmacomimetic variant and the risk
factor is zero for individuals with gij = 0, but positive for individuals with gij > 0,
this suggests that the corresponding pharmacological intervention on the risk factor is
likely to only influence the risk factor in individuals with gij > 0, and have no average
effect in those with gij = 0. However, it is unlikely that there are many individual
variants with strong interactions. This motivates the development of approaches for
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combining variants that display some evidence of interaction into a composite genetic
moderator.
Interaction tree
The interaction tree method is a recursive partitioning approach that was introduced
by Su et al. [2009]. We first present how to construct a single interaction tree, and in
the next section describe how to construct a RFIT. For each candidate split variant
Gj, we consider an indicator variable Ii for individuals indexed by i in two ways: i)
Ii = 0 for the subgroup with gij = 0 versus Ii = 1 for the subgroup with gij = 1, 2;
and ii) Ii = 0 for gij = 0, 1 versus Ii = 1 for gij = 2. We then calculate the t-statistic
for the interaction term γ3 from the model:
xi = γ0 + γ1Ii + γ2zi + γ3ziIi +
K∑
k=1
γk+3cik + εi for i = 1, . . . , N. (2)
We split the sample into two subgroups based on the candidate variant and indicator
variable combination with the greatest squared t-statistic. We continue recursively
to split each subgroup in the same way until an additional split results in a daughter
node which is below a threshold for minimum node size, at which point a terminal
node is created without the additional split. The association of the pharmacomimetic
variant with the risk factor (the treatment effect) is calculated for each terminal node.
An example tree is shown in Figure 1.
Random forest of interaction trees method
The random forest is an ensemble method which aims to reduce variance (overfitting)
inherent in individual interaction trees by aggregating multiple decision trees con-
structed from bootstrap samples [James, 2013; Breiman, 2001]. The RFIT is based
on the random forest formulation, but instead of decision trees multiple interactions
trees are incorporated [Su et al., 2018]. To construct a RFIT, we initially split the
dataset at random into a training set (2/3 of the sample) and a validation set (1/3
of the sample). We take 2000 bootstrap samples of 2/3 of the training set (4/9 of
the total dataset) and construct an interaction tree for each sample. A random set
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of candidate split variants (3/4 of all available moderating variants) is considered at
each search for an optimal interaction term to decorrelate the trees within the random
forest and so further reduce overfitting [James, 2013; Breiman, 2001]. The treatment
effect for each individual in the validation dataset is calculated using the subgroup of
individuals in their assigned terminal node based on the interaction tree constructed
on the training dataset. Separating the construction of the trees (training dataset)
and the estimation of treatment effects (validation dataset) maintains honesty of the
random forest [Wager and Athey, 2018]. Individual treatment effects are then aver-
aged across all trees within the random forest. The values of the polygenic response
score are the predicted individual treatment effects. A schematic diagram illustrating
the application of the RFIT method is shown in Figure 2.
Assessing treatment effect heterogeneity
To assess whether the predicted treatment effects differ by more than expected due to
chance alone, we calculated the weighted standard deviation of the predicted treat-
ment effects in the validation set for each tree. We consider an interaction tree with
K leaf nodes, with the predicted treatment effect for the leaf node subgroups β̂1k
where k = 1, ..., K, and the sample size of the leaf nodes nk where k = 1, ..., K. The
weighted standard deviation for the tree (σ) was defined as:
σ =
√∑K









and N is the total sample size. We calculated the average of the weighted standard
deviations across trees.
We then permuted together the outcomes, covariates, and pharmacomimetic ge-
netic variant (equivalent to randomly assigning individuals to leaf nodes represent-
ing genotypic subgroups) for individuals in the validation subset, and calculated the
weighted standard deviation of the treatment effects in 1000 permuted validation
datasets. If the average weighted standard deviation of the treatment effects is similar
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in the validation and permuted validation datasets, then there is no more variability in
the treatment effect estimates than would be expected by chance alone. We calculated
a bootstrap p-value representing the proportion of permuted validation datasets for
which the weighted standard deviation is larger for the permuted validation dataset
than the original validation dataset.
Variable importance measure
We calculated variable importance based on the formulation described by Su et al.
[2009]. The method involves the permuting each split variable individually, and cal-
culating the decrease in overall interaction when a split variable is permuted. More
important split variables should contribute to a higher decrease in overall interaction
when permuted, and vice-versa. The variable importance of a variable was then cal-
culated by averaging over its variable importance in each tree of the random forest,
separately for the training and validation sets. This allows us to identify variants that
are important effect modifiers.
Simulation study
To illustrate the approach and demonstrate the expected gain in predictive perfor-
mance when multiple moderating variants are integrated into a composite effect mod-
erator using the RFIT approach, we conducted a simulation study. We simulated
data on 500,000 individuals and 100 candidate moderating variants, and varied the
strength of the moderating variants (γint).
We drew moderating variants (g) as SNPs with minor allele frequency of 0.3 from
a binomial distribution. We drew the pharmacomimetic score (z) from a N (0, 1)
distribution. We set the main effect of the pharmacomimetic score (γ0) as 0.3, and
considered two scenarios for interaction terms:
1. In Scenario 1 (all positive), we drew Jπ interaction terms γj from a N (γint, 0.01)
distribution, and set the remaining J(1− π) interaction terms to equal zero.
2. In Scenario 2 (positive and negative), we drew bJ π
2
c interaction terms γj from
a N (+γint, 0.01) distribution, dJ π2 e interaction terms γj from a N (−γint, 0.01)
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distribution, and set the remaining J(1− π) interaction terms to equal zero.
We set π = 0.06, corresponding to 6 out of the 100 variants being true moderating
variants. The risk factor x was simulated for each individual i as:
xi = (γ0 +
∑
j
γjgij)zi + εi (5)
where εi is an error term with N (0, 1) distribution. We denote the predicted
treatment effect for the ith individual, defined as the association between the phar-
macomimetic variant and the risk factor, as δi = γ +
∑
j γjgij. We estimate δ̂i in
subsets of the population defined by the moderating variants using the RFIT method.
We trained the RFIT in the simulated training set (2/3 of the data) with a minimum
node size of 5000, and measured the predictive accuracy in the simulated testing set
(1/3 of the data). We calculate the root-mean squared error (RMSE) between the







We also calculated the predicted treatment effects using two comparison methods:
1) as a single estimated treatment effect value for all individuals in the population,
and 2) in genetic subgroups defined by a single moderating genetic variant, taken as
the variant having the strongest interaction with the pharmacomimetic score.
Example: effect modification for statins
We applied our method to investigate treatment effect heterogeneity for statins using
data from the UK Biobank study. Data were available on 502,682 participants (94% of
self-reported European ancestry) recruited between 2006 and 2010 in 22 assessment
centres throughout the UK. We considered individual-participant data on 348,629
unrelated individuals of European descent who passed extensive quality control pro-
cedures as described in Astle et al. [2016]. Briefly, we excluded participants having
non-European ancestry (self-report or judged by genetics), low call rate, or excess het-
erozygosity (> 3 standard deviations from the mean). We included only one of each set
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of related participants (third-degree relatives or closer). We also excluded individuals
with missing data on LDL-cholesterol, body mass index (BMI), or cholesterol-lowering
medication status. LDL-cholesterol was measured on blood serum samples collected
at recruitment. For individuals who reported taking cholesterol-lowering medication,
the LDL-cholesterol measurement was multiplied by a factor of 1.25 to approximate
their LDL-cholesterol level without medication. A pharmacomimetic score was con-
structed as a weighted score using six genetic variants in or around the HMGCR gene
region, as previously reported by Ference et al. [2016], and weighting by the asso-
ciations of the variants with LDL-cholesterol where effect alelles were coded as the
LDL-lowering alleles (Web Table A1, Web Figures A1-A2).
In total, 805,426 genetic variants were measured on the UK BiLEVE Axiom array
or the UK Biobank Axiom array. Around 40 million further variants were imputed
using reference data from the Haplotype Reference Consortium [Bycroft et al., 2018].
We considered all available variants outside of the HMGCR gene region (±2 megabase
pairs) with a minor allele frequency > 0.05 and an info score > 0.5 as potential mod-
erating variants. Interaction was assessed for each moderating variant in turn using
linear regression (equation 1) with main effect terms for the pharmacomimetic score
and moderating variant, an interaction term between the pharmacomimetic score and
moderating variant, and covariates (age, sex, BMI, and five principal components of
ancestry). All variants with a p-value for the interaction term below a given sig-
nificance threshold were clumped based on correlation (variant removed if r2 > 0.3
against index variant), with the variant having the lowest p-value for interaction being
preferentially selected. The set of independent variants from the clumping procedure
were then taken forward to the RFIT method. We considered interaction significance
thresholds between p < 10−4 and p < 3×10−6 and minimal node sizes of 5000, 10 000,
20 000, 30 000, and 40 000.
We note that our example differs somewhat from a standard application of Mendelian
randomization, in that we do not consider genetic associations with an outcome vari-
able. We restrict our interest to the genetic associations with LDL-cholesterol for two
reasons: first, the causal effect of LDL-cholesterol on coronary artery disease risk has
been well-established and differences in coronary artery disease risk have been shown
to be log-linear in the change in LDL-cholesterol in both trials [Cholesterol Treatment
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Trialists’ Collaboration, 2010] and Mendelian randomization investigations [Ference
et al., 2012]; and second, because interactions in the genetic associations with coro-
nary artery disease are more difficult to detect: coronary artery disease is less proximal
to the genetic variants, and the disease variable is binary and relatively uncommon.
We assume that any observed heterogeneity in the genetic associations with LDL-
cholesterol for the pharmacomimetic variant (and, by inference, in the effect of statins
on LDL-cholesterol) would lead to heterogeneity in the genetic associations with coro-




Figure 3A presents the scenario where moderating variants all have positive effects
(Scenario 1). In the setting where there are no true moderating variants (γint = 0), the
true treatment effects are identical across the population. As expected, predictions
based on a single estimated treatment effect value for all individuals outperformed
the RFIT slightly in this setting. However, as the strength of the moderating effects
increased, the degree of which the RFIT approach outperformed the other two ap-
proaches also increased. For example, at γint = 0.075, which is 1/4 the strength of
the pharmacomimetic main effect (γ0), we observed an approximate 50% decrease in
RMSE when predictions were generated by a composite effect moderator instead of a
single moderating variant.
Figure 3B presents the scenario where moderating variants can have both posi-
tive and negative effects (Scenario 2). The results were very similar to Scenario 1,
suggesting that the treatment effect predictions based on the RFIT method are not
adversely influenced when effects of moderating variants are in both directions.
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Example: effect modification for statins
Baseline characteristics of participants
Baseline characteristics of UK Biobank participants in the analytic sample are pre-
sented in Table I both for the whole sample, and for individuals with pharmacomimetic
score above and below the median value. The pharmacomimetic score was not associ-
ated with age, sex, or blood pressure. There was an association of the score with BMI,
although the magnitude of association was small. This motivates the inclusion of BMI
as a covariate in the interaction tests. There was a strong association of the phar-
macomimetic score with LDL-cholesterol and with current use of cholesterol-lowering
medication, as expected.
Gene–gene interactions
To test for the independent interaction effects between moderating variants and the
pharmacomimetic score, we conducted a genome-wide interaction search where we
applied Equation 1 separately for each j = 1, . . . , J variants. No individual genetic
variants were found that had a gene–gene interaction at a genome-wide significance
level (Web Figure A3). The quantile–quantile plot suggested that there was minimal
inflation due to population stratification, and the distribution of interactions was no
stronger than would be expected due to chance alone (Web Figure A4).
Predicted treatment effects
To construct a composite effect modifier of statins, we applied the RFIT method to
the UK Biobank cohort (Figure 2). Predicted treatment effects for all individuals
in the validation dataset are displayed in Figure 4. These effects can be interpreted
as values of the polygenic response score. For more stringent values of the p-value
threshold, the distribution of predicted treatment effects is irregular due to the small
number of moderating variants, whereas for less stringent values, the distribution
approximates a normal distribution. Effect estimates are similar for all individuals
in the population at all parameter values for the interaction significance threshold
and minimal node size. No individuals had an predicted treatment effect that was
positive, or even close to zero. This means that no genetically-defined subgroup of the
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population was identified that would not be expected to benefit from statin treatment.
Figure 5 shows the average difference between the weighted standard deviation
of treatment effect estimates in the validation and bootstrap-permuted validation
datasets. While the difference was generally positive, indicating higher identified
heterogeneity in the validation subset, it was small throughout. The bootstrap p-
value was only 0.18 at its minimum value with node size of 40 000 and interaction
p-value threshold of 7×10−6 (Web Figure A6). Hence the predicted treatment effects
were no more variable than would be expected due to chance alone.
Variable importance measure
Variants having the strongest interactions are displayed in Web Figure A5, together
with their variable importance measures. Only two variants (rs162724 and rs12884142)
displayed positive variable importance in both the training set and validation datasets,
which suggests the generalizability of these effect modifiers.
rs162724 is an intronic variant (minor allele frequency of 0.16 and interaction p-
value of 1.2× 10−6) located proximal to the GRM7 gene on chromosome 3. Previous
genome-wide association studies have found strong associations of variants within the
GRM7 gene region with major depressive disorder, schizophrenia, and the efficacy
of antipsychotic medication [Need et al., 2009; Stevenson et al., 2016; Shyn et al.,
2011; Sacchetti et al., 2017]. The use of some antipsychotics has been found to be
associated with altered risk of hyperlipidaemia, and in some studies with elevated
LDL-cholesterol levels [Meyer and Koro, 2004; Saari et al., 2004]. Thus, it is possible
that the variant (rs162724) acts as a proxy for antipsychotic use in our study, which
in turn acts an indirect effect modifier of statins by altering cholesterol levels.
Discussion
In this paper, we have introduced an agnostic approach to combine genetic variants
into a composite effect modifier (a polygenic response score) that divides the popula-
tion into genetic subgroups which are predicted to respond differently to a particular
treatment. This approach relies on the principles of Mendelian randomization that
pharmacomimetic genetic variants can be treated as if they have been randomized,
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and can be used as an unconfounded proxy for the treatment. Through a simulation
study, we have demonstrated the applicability of our approach when multiple mod-
erating variants are present. As a proof-of-concept example, we have illustrated the
approach for the effect of statins on LDL-cholesterol levels. In this example, no more
heterogeneity in the predicted treatment effect was detected than would be expected
by chance alone, the sign of the predicted treatment effect was the same for all in-
dividuals in the population, and there was no subgroup of the population for whom
the predicted treatment effect was close to zero. Therefore the clinical impact of this
finding is low. However, the approach may have more applicability in other contexts.
A proposed setting where our approach may have clinical utility is for CETP
inhibition. While CETP inhibitors have generally failed to demonstrate effectiveness
in untargeted clinical trials [Schwartz et al., 2012; Lincoff et al., 2017] (although see
[HPS3/TIMI55–REVEAL Collaborative Group, 2017]), there is some evidence for a
protective effect of dalcetrapib in a particular genotypic subgroup of the population
defined by a variant in the ADCY9 gene region [Tardif et al., 2015]. Our method could
be used to further refine this finding by searching for subgroups based on multiple
genetic variants, rather than just considering single variant interactions.
Previous attempts have been made to find genetic variants that predict response
to treatment [Lewis et al., 2019], including for statins [Postmus et al., 2014], based on
data from clinical trials. Our paper makes two additional methodological contribu-
tions to the literature. First, we use the Mendelian randomization paradigm, which
allows treatment response to be predicted from cross-sectional data. Secondly, we con-
struct a polygenic response score based on multiple variants from across the genome,
rather than just individual variants. Results from our simulation study demonstrate
that our method is especially applicable in the scenario where there are multiple mod-
erating variants. The statins example we provide may be indicative of such a scenario,
since no strong genome-wide significant gene-gene interactions were observed.
Our results provide some evidence in the wider debate as to whether treatment
effect heterogeneity is widespread or uncommon. For example, Senn [2018] argues
that treatment effect heterogeneity should not generally be expected, meaning that
precision medicine approaches are unlikely to exist for many treatments. More ex-
tensive investigations are required to judge whether the degree of effect heterogeneity
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observed in this paper is typical or not.
Since the true number of moderating variants is unknown a priori, the optimal
minimum node size setting for the RFIT is unclear. Specifically, a small minimum
node size would be preferable in scenarios where there are a large number of true
moderating variants. We thus propose the use of the weighted SD of treatment effects
as a guide to inform us of a suitable of minimum node size. For each minimum
node size, the weighted SD of the true validation set could be compared against the
permuted validation set, in order to determine if more treatment heterogeneity than
expected by chance has been captured by the RFIT. A minimum node size should
then be chosen such that more heterogeneity than chance is captured (illustrating the
presence of a signal), in order to reduce over-fitting.
Our proposed approach has strengths and also weaknesses. While it would be pos-
sible to investigate treatment effect heterogeneity more directly in a trial setting, our
approach is able to leverage the large sample sizes available in cross-sectional ‘biobank’
data. Biobank samples are often more representative of the general population than
clinical trials, meaning that estimates are obtained in a more relevant target popu-
lation, particularly if the treatment is for primary prevention. Furthermore, lack of
efficacy is the major contributor to failure of phase 3 clincal trials [Fogel, 2018]. Our
method allows prior prediction of treatment response, so that trials can be conducted
in targeted genetic subgroups. Finally, since there is usually no a priori knowledge
with regards to the types of interactions present, one of the strengths of our approach
lies in its hypothesis-free nature. Specifically, our approach offers the flexibility to
model multi-way interactions (interactions between moderating variants), but is still
able to model scenarios where there may not be interactions between moderating vari-
ants. However, there are also potential weaknesses. First, there are many reasons why
a statistical interaction may be observed that does not correspond to a biological in-
teraction. For example, it may be that moderating variants increase LDL-cholesterol
levels, and that the association of HMGCR variants with LDL-cholesterol is simply
larger in individuals with greater LDL-cholesterol levels. While this is an example
of effect modification, the conclusion that individuals with greater LDL-cholesterol
levels would benefit more from LDL-cholesterol lowering is not particularly insightful.
Secondly, our approach for identifying moderating variants was relatively simple, and
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more complex approaches could be considered. For example, we may believe that
genetic variants with strong interaction effects are likely to also have strong main
effects. Rather than considering the p-value for each interaction term in isolation,
we could consider the p-values for the main effect and the interaction effect jointly.
Thirdly, the genetic associations with LDL-cholesterol are not particularly strong,
with the strongest individual per allele genetic association corresponding to a 0.06
mmol/L change in LDL-cholesterol. In contrast, statins can reduce LDL-cholesterol
by around 1 mmol/L. Hence our null result may correspond to a lack of power. How-
ever, genetic associations typically represent lifelong changes in the trajectory of a
risk factor and so the proportional effect on a disease outcome is generally stronger
[Burgess et al., 2012], meaning that genetic interactions may be easier to detect. Also,
genetic associations do not suffer from lack of adherence that can attenuate effects
in trials. Fourthly, our method relies on the assumption that the pharmacomimetic
variants can be treated as proxies for the relevant treatment. In practice, there may
be ways in which the genetic variant does not mimic treatment use. For example,
we would not be able to detect effect modifiers which are drug metabolizers. Genetic
polymorphisms in Cytochrome P450, a drug metabolizing enzyme, has been shown
to be strongly associated with response to statins [Lynch and Price, 2007; Canestaro
et al., 2014]. It is possible that majority of the effect heterogeneity may be attributed
to drug metabolism. Finally, our results could be affected by population factors such
as ethnicity. Detecting such heterogeneity would be useful, as it would still identify
subgroups of the population that have different treatment response. However, varying
a treatment regime based on ethnicity would not generally be regarded as precision
medicine, as precision medicine seeks to find differences within populations rather
than between populations. We have tried to reduce the impact of ethnicity by re-
stricting our analysis to individuals of European descent and adjusting for genomic
principal components. However, we cannot rule out a residual effect of population
stratification on our results.
In conclusion, we have demonstrated an agnostic genome-wide approach to create
a polygenic response score that explains heterogeneity in the predicted effect of a
treatment. While the clinical impact of the example demonstrated here is limited,
this approach may be useful to detect individuals with particularly strong or weak
16
predicted response to particular treatments, leading to opportunities for precision
medicine.
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Table I: Baseline characteristics of participants: Baseline characteristics (mean
and standard deviation, or percentage) of the European ancestry subset of UK
Biobank. P-values for differences in characteristics between the subgroups below and
above the median HMGCR score are calculated using a t-test for continuous traits
and a χ2 test for categorical traits.
HMGCR score HMGCR score
Overall ≤ Median >Median p-value
(N = 348,629) (N=178,263) (N=170,366)
Age (years) 57.15± 8.03 57.17± 8.02 57.13± 8.03 0.17
Body mass index (kg/m2) 27.35± 4.75 27.30± 4.74 27.41± 4.77 2.65× 10−11
Male (%) 45.92 45.95 45.89 0.73
Systolic blood pressure (mmHg) 137.64± 18.62 137.59± 18.61 137.68± 18.62 0.14
Diastolic blood pressure (mmHg) 81.97± 10.13 81.97± 10.12 81.96± 10.14 0.77








= 0 > 0
rs162724
= 0 > 0
rs12884142
= 0 > 0
N = 48646 N = 31981
N = 34538
N = 39781
β = -0.2735 β = -0.4290
β = -0.1870
β = -0.4665
Figure 1: Example of a single interaction tree, constructed with interaction signif-
icance threshold p < 7 × 10−6 and minimum node size of 30 000. Terminal nodes





Aggregate variants proximal to 
drug target proxy gene. 
UK Biobank
( N =  487,409)
European Ancestry 
( N =  367,643)
Non-Missing Covariates








( N = 232,419)
Validation Set
( N =  116,210)




Identify strong effect moderators: 
Genome-wide scan for variants with strong 
interactions with pharmacomimetic score.
Random Forest of 
Interaction Trees
Construct composite effect moderator: 
Construct RF using bootstrap samples, and use 
effect moderating variants as predictors.
Genetic Subgroups and Individualized 
Treatment Effects
Apply validation set: 
Assign individuals to genetic 
subgroups and construct 
individualized treatment effects.
Figure 2: Summary of the RFIT method to construct the composite effect modifier
(polygenic response score) for the applied example.
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Figure 3: Simulation results illustrating the testing set root-mean squared error
(RMSE) between the predicted treatment effects and the true values. RMSE of the
treatment effect predictions based on the RFIT are compared against predictions
based on: 1) A single estimated treatment effect value for all individuals in the popu-
lation 2) Estimated treatment effect values that vary with a single moderating variant.
a) Scenario 1: Moderating effect are all positive. b) Scenario 2: Moderating effect
can be positive or negative.
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Figure 4: Histograms of predicted individual treatment effects estimated using random
forest method with different minimum node sizes and different p-value thresholds for




























Figure 5: Average difference in weighted standard deviation of the predicted subgroup
treatment effect estimates calculated in the validation dataset and boostrap-permuted
validation set based on trees estimated in the training dataset. Positive differences
indicate higher heterogeneity of predicted subgroup treatment effects identified in true
validation dataset compared to the bootstrap-permuted validation set.
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Appendix
Web Table A1: SNPs selected for the construction of pharmacomimetic score in or
around the HMGCR gene region: rsid, p-value (P) and effect size for association
with LDL-cholesterol in mmol/L (Beta), standard error (SE), chromosome (Chr) and
position number in hg19 (Pos), LDL-lowering coded allele / effect allele (A1), non-
effect allele (A2) and effect allele frequency (EAF) calculated from included samples
within the UK Biobank.
rsid P Beta SE Chr Pos A1 A2 EAF
rs12916 1× 10−226 -0.0647 0.0020 5 74656539 T C 0.60
rs17238484 2× 10−114 -0.0535 0.0024 5 74648496 G T 0.77
rs10066707 2× 10−96 -0.0427 0.0021 5 74560579 G A 0.63
rs5909 3× 10−49 -0.0499 0.0034 5 74656175 G A 0.91
rs2006760 2× 10−47 -0.0358 0.0025 5 74562029 C G 0.80



















































































Web Figure A1: r2 values illustrating the linkage disequilibrium between SNPs in-






















































































































































































































































































































74.55 74.6 74.65 74.7
Position on chr5 (Mb)
Web Figure A2: Zoomed-in Manhattan plot of genetic associations with LDL-
cholesterol for variants in and around the HMGCR gene region.
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Web Figure A3: Manhattan plot for interactions, where p-value indicates the strength
of interaction between the candidate moderating variant and HMGCR score in their
association with LDL-cholesterol.
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Web Figure A4: Quantile–quantile plot of p-values for interaction term from linear
regression using each candidate moderating genetic variant in turn. The inflation


















Web Figure A5: Variable importance of SNPs used in the construction of RFIT with
significance threshold of p < 7 × 10−6 and minimum node size of 30 000. In total, 8
SNPs had an interaction p-value below this threshold, although 2 variants were never
selected as splitting variants as they divided the validation dataset into subsets that
















































Web Figure A6: Weighted standard deviation of the predicted individual treatment
effect estimates calculated in the validation dataset based on trees estimated in the
training dataset for (left) true validation dataset and (right) bootstrap-permuted vali-
dation dataset. Error bars indicate the 2.5th to the 97.5th percentiles of the weighted
SD illustrating its variability across the 1000 bootstrapped permutations
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